Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
196-210 of 339
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Jaffer Ajani, MD
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
- advertisement
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
MinuteCE®Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Harry Yoon, MD
Jaffer Ajani, MD
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
MinuteCE®The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
CME/CESecond-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
Aditya Bardia, MD, MPH, FASCO
Tiffany Traina, MD
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
Sandra Swain, MD
Virginia Kaklamani, MD
- advertisement
Differential Diagnosis of Indolent Systemic Mastocytosis
MinuteCE®Differential Diagnosis of Indolent Systemic Mastocytosis
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Sandra Swain, MD
Virginia Kaklamani, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
